Repligen Phase III Secretin program

RGEN said it will begin 2 placebo-controlled U.S. Phase III trials of Secretin in about 300 children aged 3 to 6 with moderate to severe autism. The trials will use normal levels of biomarkers for colitis or pancreatic insufficiency, which were identified in a Phase II trial, as inclusion criteria (see BioCentury July 23). Secondary endpoints will be improvements in receptive and expressive language. ...